Cargando…

Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw

Introduction: Bone metastases are the most frequent site of secondary localization of prostate cancer (PCa) and are present in about 90% of cases of advanced disease. Consequently, an adequate management of bone involvement is of pivotal importance in the therapeutic approach and skeletal-related ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mollica, Veronica, Nuvola, Giacomo, Tassinari, Elisa, Nigro, Maria Concetta, Marchetti, Andrea, Rosellini, Matteo, Rizzo, Alessandro, Errani, Costantino, Massari, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947753/ https://www.ncbi.nlm.nih.gov/pubmed/35323342 http://dx.doi.org/10.3390/curroncol29030142

Ejemplares similares

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
por: Mollica, Veronica, et al.
Publicado: (2022)

An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
por: Mollica, Veronica, et al.
Publicado: (2021)

Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
por: Mollica, Veronica, et al.
Publicado: (2021)

The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
por: Marchetti, Andrea, et al.
Publicado: (2021)

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Osteonecrosis of the Jaw
por: Lončar Brzak, Božana, et al.
Publicado: (2023)

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer
por: Mollica, Veronica, et al.
Publicado: (2020)

Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
por: Caminha, Raquel D’Aquino Garcia, et al.
Publicado: (2019)

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis
por: Righini, Matteo, et al.
Publicado: (2022)

Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication)()
por: Baba, Akira, et al.
Publicado: (2019)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role
por: Capsoni, Franco, et al.
Publicado: (2006)

Bisphophonates related osteonecrosis of the jaw
por: Gupta, Swati, et al.
Publicado: (2013)

Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries
por: Taguchi, Akira, et al.
Publicado: (2017)

Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association
por: Marcianò, Antonia, et al.
Publicado: (2020)

Osteonecrosis of jaw associated with bisphosphonate use
por: Rastogi, Ashu, et al.
Publicado: (2012)

Bisphosphonate-related osteonecrosis of the jaws (Bronj)
por: Beninati, Francesco, et al.
Publicado: (2013)

Osteonecrosis of the jaws in patients treated with bisphosphonates
por: Ata-Ali, Fadi, et al.
Publicado: (2012)

Bisphosphonate-Related Osteonecrosis of the Jaw: Specificities
por: Paulo, Siri, et al.
Publicado: (2014)

Expert opinion about osteonecrosis of the jaw
por: Lee, Jeong Keun
Publicado: (2017)

Outcomes of Clinical Trials on Osteonecrosis of the Jaw
por: Wu, Brendan W, et al.
Publicado: (2021)

Medication-related osteonecrosis of the jaw: An update
por: Bansal, Hitesh
Publicado: (2022)

The impact of sex steroids on osteonecrosis of the jaw
por: Kim, Ranhee, et al.
Publicado: (2022)

Update on Medication Related Osteonecrosis of the Jaws
por: Boyd, Barry C.
Publicado: (2023)

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020
por: Campisi, Giuseppina, et al.
Publicado: (2020)

Use of CAD–CAM Bridging Mandibular Prosthesis in Osteonecrosis of the Jaw: The Experience of Our School
por: Ricotta, Francesco, et al.
Publicado: (2020)

Bisphosphonates and Osteonecrosis of the Jaw: A Case Report
por: Reiriz, André Borba, et al.
Publicado: (2008)

Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone
por: Villa, Alessandro, et al.
Publicado: (2011)

Imaging findings in bisphosphonate-induced osteonecrosis of the jaws
por: Popovic, Katarina Surlan, et al.
Publicado: (2010)

Evolution and Etiopathogenesis of Bisphosphonates Induced Osteonecrosis of the Jaw
por: Kumar, Vijay, et al.
Publicado: (2013)

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?
por: Cassoni, Andrea, et al.
Publicado: (2016)

RANK-Ligand inhibitor associated osteonecrosis of the jaw
por: Rashad, Ashkan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a2kh55v8fnp1919j5m6k56la3n